跳至主要内容
临床试验/NCT07158827
NCT07158827Available不适用

Expanded Access to Tavapadon

AbbVie0 个研究点开始时间: 2025年9月8日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
Available
发起方

研究概览

简要总结

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to tavapadon prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

研究设计

研究类型
Expanded Access

入排标准

性别
All
接受健康志愿者

入选标准

  • Exclusion Criteria:
  • There are other suitable treatment options.
  • The participant qualifies for ongoing clinical trials.

排除标准

  • 未提供

研究者

发起方
AbbVie
申办方类型
Industry
责任方
Sponsor

相似试验